SPLDv3

• Research type

  Research Database

• IRAS ID

  335631

• Research summary

  Secondary and Primary care Longitudinal Database (SPLD)

• REC name

  South West - Central Bristol Research Ethics Committee

• REC reference

  23/SW/0142

• Date of REC Opinion

  21 Dec 2023

• REC opinion

  Further Information Favourable Opinion

• Data collection arrangements

  This database combines information on hospital drug usage and hospital activity (HES database). The combination of these data sources creates insight into the interaction in secondary care between disease, treatment and prescribing.
  No identifiable data will be contained within the database. The pseudonymised data will contain no information on the location of the Hospital Trust, or practice, at which patients are registered. Pseudonyms used cannot be related to any identifier.
  The pseudonymised data will be held by IQVIA in a location with an ISO27001 information security certificate. Access to the data is restricted to employees or contractors of IQVIA and is strictly controlled and audited, and those with access must also sign a stringent access agreement.
  All studies using the linked data HES - prescribing data must first be submitted to IQVIA’s Independent Scientific and Ethics Advisory Committee (ISEAC).
  IQVIA will only release aggregated or tabulated data that has also been subjected to the normal HES protocol rules for release (e.g. small numbers).

• Research programme

  The community supported by this database includes researchers from academia, life sciences and regulatory bodies. Other organisations that such as patient groups, charities and the health services also benefit from insights generated with the database. The types of research that will be carried out include: - Pharmacovigilance – for example; enabling estimates of exposure to drugs in hospital for the first time and enabling assessment of risk following off label use or specific issues affecting drug use in secondary care; - Drug utilisation – for example; enabling more granular analysis of the uptake of NICE guidance and other pharmaceuticals , improving the ability of Trusts and managers to reduce hospital acquired infections and drug usage in relation to the Payments by Results (PbR) tariff; - Health economics and outcomes research – for example; enabling a more informed analysis of treatment outcomes leading to better knowledge and improved clinical decision making.

• Research database title

  Secondary and Primary care Longitudinal Database (SPLD)

• Establishment organisation

  IQVIA Ltd

• Establishment organisation address

  The Point

  37 North Wharf Road

  London

  W2 1AF